Company Description
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics.
The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia.
It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.
It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences.
The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022.
Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1967 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Anthony C. Hayes Esq. |
Contact Details
Address: 725 Fifth Avenue, 22nd Floor New York, New York 10022 United States | |
| Phone | (212) 393-4540 |
| Website | aikidopharma.com |
Stock Details
| Ticker Symbol | DOMH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000012239 |
| ISIN Number | US0088753043 |
| Employer ID | 52-0849320 |
| SIC Code | 6211 |
Key Executives
| Name | Position |
|---|---|
| Anthony C. Hayes Esq. | Chief Executive Officer and Chairman |
| Kyle Michael Wool | President and Director |
| George Michael Way CPA | Chief Financial Officer |
| Christopher Devall | Chief Operating Officer |
| Matthew B. McCullough | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 10-K | Annual Report |
| Dec 28, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| Dec 28, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 18, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |
| Nov 6, 2023 | 10-Q | Quarterly Report |
| Oct 31, 2023 | 8-K | Current Report |
| Oct 19, 2023 | 8-A12B | Registration of securities |
| Oct 17, 2023 | 8-K | Current Report |
| Oct 10, 2023 | 8-K | Current Report |